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Abstract
In oncology 2-deoxy-2-[18F]fluoro-D-glucose ([18F]-FDG), a glucose analogue, is the most used positron emission
tomography (PET) tracer. There are however some limitations due to low metabolic activity or high surrounding
physiological uptake in several tumors or regions. Investigating new tracers or methods is expensive and
elaborative when animal experiments or phase I clinical trials are used. In vitro experiments can overcome these
limitations. We analyzed the influence of incubation time, cell medium conditions, administered activity, and
cell density on [18F]-FDG uptake in six different cell cultures. Glucose transporter 1 (GLUT1)- and hexokinase 2
(HK2)-expression at high and low cell density was analyzed using immunocytochemistry. FDG-uptake increases
over time and absence of glucose in the incubation medium increases uptake. By increasing the administered
activity, uptake per protein also increases and tracer uptake per protein is lower at higher cell densities. Im-
munocytochemical analysis reveals a lower expression of both GLUT1 and HK2 at higher cell concentrations. All
investigated parameters influenced FDG uptake and therefore we can conclude it is of utmost importance to
keep administered activity, incubation medium, and time constant and to correct uptake when cell density
changes due to environmental conditions, such as therapy.
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Introduction
Today’s most widely used positron emission tomography(PET) tracer in oncology is 2-deoxy-2-[18F]fluoro-D-
glucose ([18F]FDG). As a glucose analogue its mechanism of
action relies on enhanced glucose uptake and glycolysis.1
Despite its widespread use, a number of problems and lim-
itations still exist. For oncological applications, the poor
specificity of [18F]FDG represents an important drawback.
Infections and inflammatory processes can cause false posi-
tive findings. For brain tumors and tumors in the pelvis, the
physiologic [18F]FDG uptake and excretion hamper the tu-
mor assessment. On the other hand, some tumors such as
prostate carcinoma, mucinous carcinoma, and hepatocellu-
lar carcinoma display low [18F]FDG-uptake due to low
metabolic rates or elevated glucose-6-phosphatase levels.2,3
New techniques like dynamic scanning and dual-time point
imaging are under investigation to overcome these short-
comings and improve clinical work-up of patients with PET.
When validating new tracers or when evaluating new ther-
apies and procedures using validated tracers, a thorough
knowledge of its uptake mechanism, uptake dynamics, and
stability is needed. Phase I clinical trials and animal experi-
ments are known to be elaborative, relatively expensive, and
bound by numerous regulations. These problems are not
encountered when performing in vitro experiments. How-
ever, when performing in vitro uptake experiments it is im-
portant to take into account all the different parameters that
could influence tracer-uptake to assure comparable and re-
liable results. As it is generally known that cell metabolism
and growth is influenced by factors like environmental
temperature, growth medium, and cell density, we try to
describe some practical aspects of in vitro experiments using
[18F]FDG, which is the most available PET-tracer worldwide.
For this purpose we analyzed six different cell cultures of
four different tumor types and investigated the influence of
incubation time, cell medium conditions, administered ac-
tivity, and cell density on the in vitro uptake of [18F]FDG.
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Three glioma (Hs683, F98, U-118), 1 epidermoid cancer
(Hep2), 1 hepatocellular carcinoma (HepG2), and 1 colorectal
carcinoma (HT-29) cell line were obtained from ATCC (F98,
U-118MG) or kindly provided by the department of radia-
tion oncology and experimental cancer research, Ghent
University (Hs683, Hep2, HepG2, HT-29). Cells were cul-
tured in DMEM (Invitrogen, Merelbeke, Belgium) supple-
mented with L-glutamine, penicillin, streptomycin, and
fungizone or McCoy’s 5A (Invitrogen) supplemented with
10% fetal bovine serum, L-glutamine, penicillin, and strep-
tomycin. Cell culture medium was refreshed twice a week
and cultures were kept in the exponential growth phase at
37C and 5% CO2.
Uptake experiments
Analysis of the influence of incubation time on [18F]FDG-
uptake was done using the LigandTracer device (Ridge-
view, Uppsala, Sweden). Briefly, cells were seeded in 3mL of
incubation medium at one end of a Petri dish and the dish
was placed inclined in the incubator for at least 6 hours
giving the cells time to adhere to the dish. Afterward, the
dish was washed, fresh medium was administered, and the
dish was placed back in a normal position at 37C and 5%
CO2. Two to 4 days after seeding, the dish was washed with
phosphate-buffered saline (PBS), and 10lCi of [18F]FDG was
diluted in 3mL PBS and added after placing the dish in the
device. By sequentially measuring the side of the dish with
and without cells, uptake was quantified in counts per sec-
ond in an easy way for up to 2 hours (Fig. 1).
For analysis of the influence of tracer activity, incubation
medium, and cell density on [18F]FDG-uptake, cells were
seeded in 12-well plates (BD, Erembodegem, Belgium). Cells
were allowed to grow and attach for at least 48 hours. In
experiments evaluating the influence of tracer activity and
incubation medium, a constant number of cells were seeded.
In experiments evaluating the influence of cell density, dif-
ferent cell concentrations were seeded. When different tracer
activities were administered, a standard sample of the in-
cubation solution was measured to calculate the percentage
uptake of the administered activity. 1, 10, or 100 lCi of
[18F]FDG was diluted in 1mL of either PBS or cell culture
medium and added to each well. After a 60 minutes incu-
bation period at 37C and 5% CO2, cells were washed three
times with ice-cold PBS and lysed in 0.5mL RIPA-buffer
(Thermo Scientific, Rockford, IL). Cell lysates were coun-
ted using an automated gamma counter (Cobra II series;
Canberra-Packard, Meriden, CT). Protein concentration of
each sample was determined using the BCA protein assay kit
(Pierce, Rockford, IL) according to the manufacturer’s rec-
ommendations and bovine serum albumin (BSA) was used
as protein standard. Uptake/well was corrected for protein
concentration in the experiments investigating cell density.
Immunocytochemical staining
For immunocytochemical staining of glucose transporter 1
(GLUT1) and hexokinase 2 (HK2) cells were seeded in dif-
ferent cell concentrations in wells of Labtek polystyrene
slides (BD). After removal of the plastic box, cells were fix-
ated in 4% paraformaldehyde (Klinipath, Olen, Belgium).
The endogenous peroxidase activity was blocked for 5 min-
utes with 0.3% hydrogen peroxide (Dako, Glostrup, Den-
mark). Slides were incubated with primary antibodies
diluted in 1 · PBS with 1% BSA for 1 hour at room tem-
perature (GLUT1 ABCAM ab15309, HK2 Santa-Cruz
sc-28889). After washing, the tissue sections were incubated
for 30 minutes at room temperature with a labeled polymer-
HRP antirabbit secondary antibody (Dako). After washing,
the tissue sections were counterstained with Mayer’s hema-
toxylin. An Optronics color digital camera (Olympus Cor-
poration, Tokyo, Japan) and specialized software (Cell D
Olympus Imaging Solutions, Mu¨nster, Germany) was used
to analyze immunocytochemical stainings. Slides were vi-
sually analyzed for both intensity and percentage of positive
tumor cells in confluent and subconfluent wells.
Statistical analysis
All experiments were performed in triplicate and repeated
three times. Because of the descriptive nature of our staining
results neither scores nor statistical analysis is provided.
Results
Incubation time
LigandTracer-technology was used to measure [18F]FDG-
uptake in real-time to quantify uptake in tumor cells
throughout time. We observed an increase in [18F]FDG-
uptake over a time period of 120 minutes. Results of these
experiments are shown in Figure 2.
Incubation medium
[18F]FDG-uptake was measured after incubation in both
PBS and normal cell culture medium (DMEM and in case of
HT-29 cells in McCoy’s). The [18F]FDG solution has a glu-
cose level below 20mg/dL whereas DMEM has around
100mg/dL and McCoy’s 300mg/dL. [18F]FDG-uptake in cell
culture media was lower compared with PBS as incubation
medium. This was the case for all cell lines tested (Fig. 3).
FIG. 1. Principle of uptake experiments using LigandTracer
device. Tumor cells are specifically grown at one end of the
dish. The dish is placed inclined in the device with radio-
active tracer present in the incubation medium. When the
dish rotates, places with/without tumor cells sequentially
pass the detector, measuring uptake of radioactivity in real-
time. PBS, phosphate-buffered saline.
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Tracer activity
Next, we investigated the influence of administration of
different tracer activities in in vitro experiments. Therefore,
[18F]FDG-uptake was measured after the addition of 1, 10,
and 100 lCi of [18F]FDG. In addition, these experiments
were conducted in both PBS and cell growth medium.
When 100 lCi of [18F]FDG was administered the highest
percentage of the administered activity was retained in
the cells. We observed a much higher accumulation of
[18F]FDG when PBS was used compared with cell medium
(Fig. 4). Further, uptake was dependent of the cell line
and there’s a slightly higher accumulation at higher tracer
activities.
Cell density
To test the influence of cell number on [18F]FDG-uptake
we performed experiments with different cell concentra-
tions and kept incubation time, medium, and activity con-
stant. [18F]FDG-uptake was determined using 10 lCi of
tracer in a PBS solution during 60 minutes. Results are
summarized in Figure 5. We observed a trend toward lower
uptake at higher cell concentrations except in the case of
HepG2 cells where the effect was less pronounced. Further,
FIG. 2. [18F]FDG-uptake over time. [18F]FDG-uptake in
CPS is expressed over time in minutes for all six different
cells. We observe an increase in all cell cultures. CPS are
measured in predefined areas containing cells of the dish and
corrected for background activity in areas without cells.
[18F]FDG, 2-deoxy-2-[18F]fluoro-D-glucose; CPS, counts per
second.
FIG. 3. [18F]FDG -uptake in different incubation media.
Results of [18F]FDG-uptake in different incubation media are
shown for all tested cell cultures where cell number and tracer
activity are kept constant. In all investigated cell lines the
percentage of the administered activity that was retained in-
side the cells was higher when PBS was used as incubation
medium compared with cell culture-specific growth medium.
FIG. 4. [18F]FDG-uptake in PBS and cell culture medium.
Percentage of total administered activity retained in the cells
is given for all situations. Results are expressed as the mean
of three independent experiments with standard error of the
mean.
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there’s a larger spread of uptake at lower cell concentrations
(Fig. 5).
Immunocytochemical staining
To define the possible influence of GLUT1- and HKII-
expression on [18F]FDG-uptake we stained cells at different
cell concentrations (Fig. 6). Cells at higher cell concentrations
appear to have less expression of both GLUT1 and HKII-
proteins.
Discussion
This paper aims to describe important parameters which
should be monitored and taken into account when con-
ducting in vitro uptake experiments. Experiments were done
FIG. 5. Influence of cell density on [18F]FDG-uptake. [18F]FDG-uptake at different cell concentrations is given. Results are
expressed as counts per minute/protein concentration and given in a scatterplot with their corresponding total protein
concentration for each well.
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using [18F]FDG but the concept and ideas can be extrapo-
lated to other metabolic tracers. For example, standard
incubation media such as DMEM, McCoy’s, and RPMI
contain certain amounts of methionine, tyrosine, and choline
which are currently being investigated for their feasibility as
radiopharmaceuticals.
Our results show that [18F]FDG-uptake increases over
time in tumor cells in vitro. It has been previously shown that
[18F]FDG linearly increases over time in tumor tissue in vivo.4
The same pattern was seen in vitro in endothelial cells.5 This
could be explained by a nonsaturable uptake and phos-
phorylation or trapping mechanism, implying [18F]FDG-
uptake increases over time until radioactive tracer is cleared
from the blood in vivo or incubation medium in vitro.6 These
results could favor delayed imaging with [18F]FDG in the
clinical setting, because of increasing tumor-to-normal ratios
over time, assuming a higher increase in tumor cells, com-
pared with normal or inflammatory tissue.7,8 Further, ex-
periments using dynamic scanning in different pathologies
are promising to improve the discrimination between benign
and malignant lesions, relying on the different uptake
kinetics.9
The procentual uptake of [18F]FDG was clearly influenced
by the presence of glucose in incubation medium during
uptake. It is recommended that patient fasts 6h before
[18F]FDG administration and blood glucose levels are
checked before tracer-injection and do not exceed 120mg/
dL. If we apply these recommendations on the in vitro set up,
DMEM (glucose concentration of 100mg/dL) is probably the
most ‘‘physiological’’ culture medium for [18F]FDG uptake
experiments.
In another experiment we investigated the influence on
[18F]FDG-uptake with variable tracer activities. Both PBS and
cell culture medium were used during incubation. We ob-
served that slightly higher percentages of administered ac-
tivity were retained when higher tracer activities were used.
Results with PBS were slightly different from those with cell
culture medium. Using cell culture medium, differences be-
tween the different tracer activities appear to be smaller. This
is probably due to the levels of glucose which are present in
the medium.
When [18F]FDG-uptake was quantified in experiments with
varying cell concentrations, keeping incubation medium, time,
and tracer activity constant, we saw a trend toward more
reproducible and lower tracer-uptake at higher cell concen-
trations. Different uptake characteristics when comparing re-
sults obtained in HT29 and HepG2 cells with results obtained
in the other cell lines can be explained by the growth char-
acteristics of the HT29 and HepG2 cell lines. Monolayers of
these cell cultures tend to grow together in clumps. This cre-
ates a heterogenous population of contact-inhibited cells in the
center and proliferative, metabolically more active cells in the
edges of these clumps. The other cell lines show a more ho-
mogeneous growth pattern with individual cells. Therefore it
can be important to describe the growth characteristics of the
tested cells when performing in vitro uptake experiments. A
similar effect of cell density on uptake of labeled thymidine
and [18F]FDGwas described by Sasajima et al. in glioma cells.6
FIG. 6. Immunocyto-
chemical staining for Glut1
and HKII. Photographs
(200 · ) of stained slides of
five different cell lines (F98,
Hep2, HepG2, Hs683, HT29)
with confluent and
subconfluent regions. Color
images available online at
www.liebertonline.com/cbr
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To test whether differences in tracer uptake could be
related to molecular changes in confluent cells we immu-
nocytochemically stained different cell concentrations for
two relevant metabolic proteins. Confluent cells appear to
have lower immunocytochemical staining for GLUT and
HKII compared with subconfluent cells. It is however very
hard to define the exact ratio and rate-limiting step between
the two systems involved in [18F]FDG-retention as men-
tioned in a review by Smith.6,10 We assume that changes in
one of the two investigated proteins can lead to increased/
decreased tracer-uptake. Therefore a decreased [18F]FDG-
uptake in higher cell concentrations can theoretically be
explained by the effect of contact-inhibition with decreased
metabolic activity of the cells. It remains however unclear
whether this is the only parameter involved in the observed
differences. Therefore, care should be taken to avoid very
low cell concentrations because the spread of quantitative
[18F]FDG-uptake increases toward lower cell concentra-
tions. Further we believe that when one wants to analyze
the effect of test substances on tracer uptake, an uptake
curve for different cell concentrations should be used as
control.
Conclusions
We observed a clear impact of all tested parameters like
incubation time and medium, tracer activity, and cell density
on the uptake of [18F]FDG. To yield similar results over
several days, a constant tracer activity should be adminis-
tered in either PBS or cell culture medium, although medium
appears to be the method of choice. When one wants to
analyze the effect of therapy on tracer uptake care should be
taken in standardizing environmental conditions such as
tracer activity and incubation time and medium. Corrections
for cell density should be performed using a standardized
uptake curve for different cell concentrations.
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